Sonja Nelson

Form D signer

Sonja Nelson

Chief Financial Officer at CoRegen

Form D signer

Capital raised by CoRegen

$96.9M+$13.5M latest round

3 Form D filings · first filed Jan 2025 · Aspen, CO

CURRENT ROLE: Chief Financial Officer
SECTOR: Biotech
COMPANY FILINGS: 3
TEAM ON FILE: 4
FOUNDED: 2022
30D INTEREST: 1 ↗

Career

1 company on file · founded 2022

CoRegenBiotech · Aspen, COsince 2022

Chief Financial Officer

Signatory on CoRegen's Form D filings · $96.9M raised across 3

Company filings

via EDGAR · Form D for CoRegen3

DateCompanyFormAmountRole on filing

Oct 28, 2025CoRegenForm D+$13.5MChief Financial Officer

Form DOct 28, 2025 · CoRegen+$13.5Mas Chief Financial Officer

Apr 21, 2025CoRegenForm D+$62.6MChief Financial Officer

Form DApr 21, 2025 · CoRegen+$62.6Mas Chief Financial Officer

Jan 19, 2025CoRegenForm D+$20.8MChief Financial Officer

Form DJan 19, 2025 · CoRegen+$20.8Mas Chief Financial Officer

Overview

Last filing Oct 28, 2025

Sonja Nelson is on file as Chief Financial Officer at CoRegen in Aspen, CO. CoRegen has 3 Form D filings on record, $96.9M raised in total. Sonja Nelson appears as a signatory on the company's filings.

Teammates

CoRegen · 3

John C. Thomas Jr.Chief Financial Officer of the IssuerSigner Jonathan SimonsDirector Peter GelinasExecutive Officer

Products

CoRegen · 1

Novel Cancer TherapyCancer Therapy

CoRegen's main product is a cutting-edge cancer therapy designed to modify regulatory T cells (Tregs) with the aim of eliminating tumors and preventing their recurrence. The therapy focuses on effectively enhancing the immune response against cancer cells.